Chandan Healthcare Limited reported a 21.4% increase in reported net profit to ₹27.06 Cr for the financial year ended March 31, 2026, while total income rose 20.4% to ₹280.67 Cr. The company achieved this growth through a balanced business model spanning B2C retail diagnostics, B2B institutional partnerships, and B2G government PPP contracts across 62 cities and 16 states. EBITDA for the year surged 31% to ₹56.84 Cr, with margins expanding to 20.25% from 18.62% in the previous year.

For the quarter ended March 31, 2026 (Q4 FY26), the company posted a reported net profit of ₹6.92 Cr, an increase of 14.9% from ₹6.02 Cr in the corresponding period of the previous year. Total income for Q4 FY26 stood at ₹77.41 Cr, compared to ₹65.07 Cr in Q4 FY25. EBITDA for the quarter was ₹14.25 Cr, with margins at 18.41%. The operational performance was supported by an aggressive multi-city rollout of exclusive partnerships and government PPP projects with a 10-year tenure ensuring long-term revenue visibility across Punjab, Assam, and Haryana.

Consolidated Financial Performance

The company’s financial statements for FY26 reflect strong growth across key metrics. Operating income for the year reached ₹276.39 Cr, up from ₹230.12 Cr in FY25. Total expenditure increased to ₹223.83 Cr from ₹189.67 Cr in the prior year. Profit before tax (PBT) for FY26 was ₹41.18 Cr, a rise of 28.4% from ₹32.07 Cr in FY25. Minority interest for the year was reported at ₹1.50 Cr.

Q4 & FY26 Profit & Loss Summary

Operational Highlights and Strategic Outlook

Chandan Healthcare operates through a company-owned model with 360 collection centres and 78+ diagnostic centres and labs. The company conducted 88 lakh+ tests in FY26. Its service portfolio includes NABL/NABH-accredited pathology and radiology solutions. The B2C segment contributed ₹111 Cr (40%) to FY26 revenue, serving 20L+ patients, while B2B and B2G segments each contributed ₹83 Cr (30%).

The company is expanding its footprint into neighboring states including Delhi, Rajasthan, Bihar, Chhattisgarh, Madhya Pradesh, Punjab, Maharashtra, West Bengal, Gujarat, Assam, and Haryana. Future initiatives include launching PET-CT centres at Gorakhpur and Kanpur and a Genome Lab in Lucknow. The company listed on NSE Emerge on February 17, 2025, and its stock price stood at ₹212.75 as on June 22, 2026, with a market capitalization of ₹520.22 Cr.

Chandan Healthcare Limited has informed the National Stock Exchange of India that it received a notice from the Registrar of Companies (ROC), Uttar Pradesh, concerning a complaint against the company. The notice, bearing reference number TC/Comp/RKV/CHANDAN/2026/764 to 771 and dated May 20, 2026, was received by the company on June 15, 2026. The ROC has directed the company to provide para-wise clarifications and documentary proof regarding the allegations raised by the complainant, Shri Rajesh Singh Dayal, within 15 days of the notice.

The complaint alleges serious financial irregularities, including the booking of bogus expenditures amounting to ₹7,66,36,770.00 and the creation of fictitious liabilities. The forensic audit report dated January 31, 2026, prepared by M/s R.M. LALL & Co., Chartered Accountants, reportedly highlighted these discrepancies, which include sham transactions and the rerouting of funds to associates of the Chandan Group. The complainant also cited anomalies in the Red Herring Prospectus dated February 4, 2025, issued by Chandan Healthcare Limited , regarding the status of partly paid shares.

The ROC's subsequent communication dated June 9, 2026, emphasized that no reply had been received from the company and demanded a response within 10 days. The regulator warned that failure to comply would result in necessary action against the company and its directors under the provisions of the Companies Act, 2013.

Key Financial Irregularities Cited

The complaint details several specific financial manipulations uncovered during the forensic investigation. The alleged bogus expenditures were recorded under various heads, including professional fees, salary, and performance bonuses, despite the company being in a pre-operative construction phase.

Further allegations include the misrepresentation of funds received from Chandan Group entities as secured borrowings rather than call money or capital contributions. The notice also points to the issuance of equity shares to Chandan Group entities without the full realization of allotment money, violating Rule 14(5) of the Companies (Prospectus and Allotment of Securities) Rules, 2014.

Chandan Healthcare Limited stated in its filing that it is in the process of submitting its response and clarifications along with supporting documents to the concerned authority. The company assured that it would extend full cooperation in the matter. The enclosed notice was submitted to the exchange for information and record.